https://www.biopharmawatch.com/news/BMRN/biomarin-advances-achondroplasia-hypochondroplasia-treatment BiopharmaWatch en 2026-10-09T13:05:00.000Z BioMarin Presents New Data Advancing Understanding of Achondroplasia and Hypochondroplasia Treatment at the American Society for Bone and Mineral Research Annual Meeting https://www.biopharmawatch.com/news/HCWB/hcw-biologics-ind-application-solid-tumors BiopharmaWatch en 2026-10-09T13:00:00.000Z HCW Biologics Maintains Momentum Toward Completion of IND Application for Clinical Study to Evaluate Lead T-Cell Engager in Solid Tumors https://www.biopharmawatch.com/news/MLYS/mineralys-lorundrostat-aha-hypertension-sessions-2026 BiopharmaWatch en 2026-10-09T13:00:00.000Z Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026 https://www.biopharmawatch.com/news/CLGN/collplant-announces-private-placement-3-7-million BiopharmaWatch en 2026-10-09T13:00:00.000Z COLLPLANT ANNOUNCES A $3.7 MILLION PRIVATE PLACEMENT https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-greg-dipasquale-cco BiopharmaWatch en 2026-10-09T12:30:00.000Z Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer https://www.biopharmawatch.com/news/NTRA/fda-breakthrough-device-natera-multi-cancer-assay BiopharmaWatch en 2026-10-09T12:00:00.000Z FDA Grants Breakthrough Device Designation for Natera’s Multi-Cancer Early Detection Assay https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-cvr-agreement-shareholder-participation BiopharmaWatch en 2026-10-09T12:00:00.000Z Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation in Potential Priority Review Voucher Value https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-revera-301-european-participant BiopharmaWatch en 2026-10-09T12:00:00.000Z Milestone Pharmaceuticals Announces First European Study Participant Enrolled in ReVeRA-301 Phase 3 Clinical Trial https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-maxim-growth-summit-2026 BiopharmaWatch en 2026-10-09T12:00:00.000Z Nuvectis Pharma to Participate in the Maxim Growth Summit 2026 https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-acg-ueg-conferences-2026 BiopharmaWatch en 2026-10-09T12:00:00.000Z Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences https://www.biopharmawatch.com/news/QNCX/quince-therapeutics-relaunches-irulya-therapeutics BiopharmaWatch en 2026-10-09T12:00:00.000Z Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease https://www.biopharmawatch.com/news/FLNA/filana-therapeutics-maxim-growth-summit-2026 BiopharmaWatch en 2026-10-09T12:00:00.000Z Filana Therapeutics to Participate in the 2026 Maxim Growth Summit https://www.biopharmawatch.com/news/TLX/profound-telix-co-education-agreement-psma-prostate-care BiopharmaWatch en 2026-10-09T11:45:00.000Z Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-present-canaccord-genuity-drug-device-conference BiopharmaWatch en 2026-10-09T11:05:00.000Z Alterity Therapeutics to Present at the Canaccord Genuity Drug and Device Conference https://www.biopharmawatch.com/news/XFOR/x4-pharmaceuticals-virtual-investor-day-october-2026 BiopharmaWatch en 2026-10-09T11:00:13.000Z X4 Pharmaceuticals to Host Virtual Investor Day on Thursday, October 29, 2026, Featuring Key Opinion Leaders https://www.biopharmawatch.com/news/JNJ/johnson-johnson-icotyde-long-term-results-plaque-psoriasis BiopharmaWatch en 2026-10-09T11:00:00.000Z New Johnson & Johnson ICOTYDE® (icotrokinra) long-term data demonstrate robust 2-year results in the treatment of adults and adolescents with plaque psoriasis https://www.biopharmawatch.com/news/TEVA/teva-fda-approval-weltruza-olanzapine-injection BiopharmaWatch en 2026-10-09T11:00:00.000Z Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia https://www.biopharmawatch.com/news/SPTX/seaport-therapeutics-glyphago-phase-1-data-ecnp-2026 BiopharmaWatch en 2026-10-09T11:00:00.000Z Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress https://www.biopharmawatch.com/news/GKOS/glaukos-phase-4-trial-idose-tr-cataract-surgery BiopharmaWatch en 2026-10-09T11:00:00.000Z Glaukos Announces Positive Topline Results from Phase 4 Prospective Randomized Controlled Clinical Trial Evaluating iDose® TR in Combination with Cataract Surgery https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-inducement-grants-nasdaq-listing-rule-5635-c-20261009 BiopharmaWatch en 2026-10-09T11:00:00.000Z Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/SGMT/sagimet-denifanstat-phase-3-results-dermatology-conference BiopharmaWatch en 2026-10-09T11:00:00.000Z Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermatology Conference https://www.biopharmawatch.com/news/LLY/new-phase-3b-data-lilly-taltz-zepbound-psoriasis-obesity BiopharmaWatch en 2026-10-09T10:45:00.000Z New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) advance understanding of the interconnected immune and metabolic biology in adults with psoriasis and obesity https://www.biopharmawatch.com/news/ALMS/alumis-phase-3-envudeucitinib-psoriasis-data BiopharmaWatch en 2026-10-09T08:00:00.000Z Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures https://www.biopharmawatch.com/news/PHVS/deucrictibant-phase-3-study-results-hai-attack BiopharmaWatch en 2026-10-08T22:35:00.000Z Phase 3 Study Results Highlighting Deucrictibant’s Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet https://www.biopharmawatch.com/news/CVS/aetna-2027-star-ratings-clinical-quality-member-experience BiopharmaWatch en 2026-10-08T22:03:00.000Z Aetna 2027 Star Ratings Reflect Strong Clinical Quality and Member Experience https://www.biopharmawatch.com/news/ALHC/alignment-healthcare-cms-2027-star-ratings BiopharmaWatch en 2026-10-08T21:00:00.000Z Alignment Healthcare Earns 4 Stars or Higher for Six of Seven Eligible Medicare Advantage Contracts in CMS 2027 Star Ratings https://www.biopharmawatch.com/news/AGEN/armenian-authorization-agenus-bot-bal-mcrc BiopharmaWatch en 2026-10-08T20:41:00.000Z Riassunto: L’Armenia concede le prime autorizzazioni alla commercializzazione di Agenus BOT+BAL per la terapia del carcinoma colorettale metastatico MSS già trattato https://www.biopharmawatch.com/news/AGEN/armenian-approval-for-agenus-bot-bal-mcrc BiopharmaWatch en 2026-10-08T20:41:00.000Z Samenvatting: Armenië verleent eerste vergunningen om Agenus’ BOT+BAL ten behoeve van eerder behandeld MSS gemetastaseerd colorectaal carcinoom in de handel te brengen https://www.biopharmawatch.com/news/AGEN/armenien-marktzulassungen-bot-bal-agenus BiopharmaWatch en 2026-10-08T20:40:00.000Z Armenien erteilt erste Marktzulassungen für BOT+BAL von Agenus bei zuvor behandeltem MSS-metastasiertem Kolorektalkarzinom https://www.biopharmawatch.com/news/SION/sionna-therapeutics-nacfc-2026-data-presentation BiopharmaWatch en 2026-10-08T20:30:07.000Z Sionna Therapeutics to Present Data at the 2026 North American Cystic Fibrosis Conference https://www.biopharmawatch.com/news/CON/concentra-third-quarter-2026-results-announcement BiopharmaWatch en 2026-10-08T20:30:00.000Z Concentra to Announce Third Quarter 2026 Results on Thursday, November 5, 2026 https://www.biopharmawatch.com/news/ZTS/zoetis-fourth-quarter-2026-dividend BiopharmaWatch en 2026-10-08T20:15:00.000Z Zoetis Declares Fourth Quarter 2026 Dividend https://www.biopharmawatch.com/news/BDX/bd-announces-financial-results-q4-fiscal-2026 BiopharmaWatch en 2026-10-08T20:15:00.000Z BD to Announce Financial Results for its Fourth Quarter and Full Year of Fiscal 2026 https://www.biopharmawatch.com/news/BKD/brookdale-reports-september-2026-occupancy BiopharmaWatch en 2026-10-08T20:15:00.000Z Brookdale Reports September 2026 Occupancy https://www.biopharmawatch.com/news/GH/guardant-health-guardant360-cdx-approval-europe BiopharmaWatch en 2026-10-08T20:12:00.000Z Guardant Health Announces Approval in Europe of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced ER-positive Breast Cancer https://www.biopharmawatch.com/news/DNA/ginkgo-bioworks-autonomous-lab-nsf-x-labs BiopharmaWatch en 2026-10-08T20:10:00.000Z Ginkgo Bioworks to Provide Autonomous Lab Access to NSF X-Labs Researchers, Contributing Cloud Lab Time and Protein Testing Services to $1.5 Billion Breakthrough Science Program https://www.biopharmawatch.com/news/ILMN/illumina-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-08T20:06:00.000Z Illumina to Announce Third Quarter 2026 Financial Results on Thursday, October 29, 2026 https://www.biopharmawatch.com/news/AGMB/agomab-ontunisertib-ueg-week-2026 BiopharmaWatch en 2026-10-08T20:05:08.000Z Agomab to Present STENOVA Open-Label Extension Data of Ontunisertib at UEG Week 2026 and Host Scientific Symposium on Fibro-Inflammation https://www.biopharmawatch.com/news/OCS/oculis-publishes-notifications-transactions-persons-discharging-managerial-20261008 BiopharmaWatch en 2026-10-08T20:05:07.000Z Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities https://www.biopharmawatch.com/news/ALMR/alamar-biosciences-q3-2026-financial-results BiopharmaWatch en 2026-10-08T20:05:00.000Z Alamar Biosciences to Report Third Quarter 2026 Financial Results on November 3, 2026 https://www.biopharmawatch.com/news/NBP/novabridge-biosciences-givastomig-esmo-2026 BiopharmaWatch en 2026-10-08T20:05:00.000Z NovaBridge Biosciences Announces Expanded Givastomig Safety and Efficacy Data to be Presented at the European Society for Medical Oncology 2026 https://www.biopharmawatch.com/news/ABCL/abcellera-phase-1-2-data-abcl635-tms-2026 BiopharmaWatch en 2026-10-08T20:05:00.000Z AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-mps-iiib-data-presentation BiopharmaWatch en 2026-10-08T20:05:00.000Z Spruce Biosciences Announces Presentation of MPS IIIB Natural History Data at the 55th Child Neurology Society Annual Meeting https://www.biopharmawatch.com/news/GH/guardant-health-third-quarter-2026-results BiopharmaWatch en 2026-10-08T20:05:00.000Z Guardant Health to Report Third Quarter 2026 Financial Results on November 5, 2026 https://www.biopharmawatch.com/news/LKFT/lakefront-transparantieverklaring-bank-of-america BiopharmaWatch en 2026-10-08T20:01:00.000Z Lakefront ontvangt transparantieverklaring van Bank of America https://www.biopharmawatch.com/news/LKFT/lakefront-receives-transparency-notification-bank-america BiopharmaWatch en 2026-10-08T20:01:00.000Z Lakefront Receives Transparency Notification from Bank of America https://www.biopharmawatch.com/news/HIT/health-in-tech-launches-hitrx-broker-first-environment BiopharmaWatch en 2026-10-08T20:00:00.000Z Health In Tech Launches HitRix, a Broker-First Environment for Self-Funded Stop-Loss Placement https://www.biopharmawatch.com/news/STAA/staaar-surgical-names-andrew-pilon-vp-business-development BiopharmaWatch en 2026-10-08T19:14:00.000Z STAAR Surgical Names Andrew Pilon as Vice President of Business Development https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-4-million-financing BiopharmaWatch en 2026-10-08T17:30:00.000Z WallachBeth Capital Announces bioAffinity Technologies Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-financing-common-stock BiopharmaWatch en 2026-10-08T16:07:00.000Z bioAffinity Technologies, Inc. Announces Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules https://www.biopharmawatch.com/news/CODX/co-diagnostics-vector-smart-laboratory-ute-tribe BiopharmaWatch en 2026-10-08T13:26:00.000Z Co-Diagnostics Announces First Full Vector Smart® Laboratory Installation for Native American Tribe https://www.biopharmawatch.com/news/SXTC/china-sxt-pharmaceuticals-12-million-offering BiopharmaWatch en 2026-10-08T13:22:00.000Z China SXT Pharmaceuticals Inc. Announces $12 Million Registered Direct Offering https://www.biopharmawatch.com/news/BFRI/biofrontera-fda-application-ameluz-actinic-keratoses BiopharmaWatch en 2026-10-08T13:22:00.000Z Biofrontera Submits Supplemental New Drug Application to FDA to Expand Ameluz® Red Light PDT to Actinic Keratoses on the Full Body https://www.biopharmawatch.com/news/DARE/dare-bioscience-phase-1-sildenafil-cream-data-smsna BiopharmaWatch en 2026-10-08T13:15:00.000Z Daré Bioscience to Present Phase 1 Sildenafil Cream Data at Sexual Medicine Society of North America (SMSNA) Annual Fall Scientific Meeting https://www.biopharmawatch.com/news/ILMN/illumina-releases-spliceai2-advance-rare-disease-research BiopharmaWatch en 2026-10-08T13:15:00.000Z Illumina releases SpliceAI2 to help advance rare disease research https://www.biopharmawatch.com/news/PHG/philips-global-clinical-advisory-board-oral-care BiopharmaWatch en 2026-10-08T13:00:00.000Z Philips Oral Healthcare Establishes Global Clinical Advisory Board to Help Shape the Future of Oral Care Through Scientific and Clinical Insight https://www.biopharmawatch.com/news/MYGN/sophia-genetics-myriad-genetics-collaboration-prgis BiopharmaWatch en 2026-10-08T13:00:00.000Z SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-financial-restructuring-capital-improvements BiopharmaWatch en 2026-10-08T13:00:00.000Z ADC Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements https://www.biopharmawatch.com/news/IMNN/imunon-participate-investor-conferences-october-2026 BiopharmaWatch en 2026-10-08T13:00:00.000Z IMUNON to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/MYGN/myriad-genetics-sophia-genetics-collaboration-prostate-cancer BiopharmaWatch en 2026-10-08T13:00:00.000Z Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology https://www.biopharmawatch.com/news/PRVA/privia-health-third-quarter-2026-results BiopharmaWatch en 2026-10-08T13:00:00.000Z Privia Health to Report Third Quarter 2026 Results on Thursday, November 5 https://www.biopharmawatch.com/news/FEMY/femasys-asrm-2026-exhibit BiopharmaWatch en 2026-10-08T13:00:00.000Z Femasys to Exhibit at the ASRM 2026 Scientific Congress & Expo https://www.biopharmawatch.com/news/NAGE/restore-niagen-longevity-month-october BiopharmaWatch en 2026-10-08T12:57:00.000Z Restore Hyper Wellness® and Niagen Bioscience Team Up to Help Americans Age Better This October https://www.biopharmawatch.com/news/NAGE/andrew-shao-awarded-annette-dickinson-trailblazer-award BiopharmaWatch en 2026-10-08T12:32:00.000Z Andrew Shao, Ph.D., Senior Vice President of Global Regulatory and Scientific Affairs at Niagen Bioscience, Honored with the 2026 Annette Dickinson Trailblazer Award by Radicle Science and Council for Responsible Nutrition (CRN) https://www.biopharmawatch.com/news/IBRX/immunitybio-participate-piper-sandler-oncology-symposium BiopharmaWatch en 2026-10-08T12:30:00.000Z ImmunityBio to Participate in the Piper Sandler Virtual Oncology Symposium https://www.biopharmawatch.com/news/VIR/vir-biotechnology-fda-fast-track-vir-5500 BiopharmaWatch en 2026-10-08T12:30:00.000Z Vir Biotechnology Announces PSMA-targeted PRO-XTEN® Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate Cancer https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-presents-late-breaking-data-aha-2026 BiopharmaWatch en 2026-10-08T12:30:00.000Z CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2026 https://www.biopharmawatch.com/news/NXL/nexalin-technology-compliance-nasdaq-minimum-bid-price BiopharmaWatch en 2026-10-08T12:30:00.000Z Nexalin Technology Regains Compliance with Nasdaq Minimum Bid Price Requirement; Nasdaq Hearings Panel Grants Request for Continued Listing https://www.biopharmawatch.com/news/BFLY/butterfly-network-q3-2026-financial-results BiopharmaWatch en 2026-10-08T12:05:00.000Z Butterfly Network to Report Third Quarter 2026 Financial Results on October 29, 2026 https://www.biopharmawatch.com/news/MDCX/medicus-pharma-three-years-progress-long-term-value BiopharmaWatch en 2026-10-08T12:00:19.000Z Medicus Pharma Highlights Three Years of Progress and Outlines Potential Path to Long Term Value https://www.biopharmawatch.com/news/BHST/tate-lyle-bioharvest-sweetener-milestone BiopharmaWatch en 2026-10-08T12:00:00.000Z Tate & Lyle and Bioharvest Reach Key Milestone in Next-Generation Sweetener Development Programme https://www.biopharmawatch.com/news/SRRK/scholar-rock-resubmits-apitegromab-maa-ema BiopharmaWatch en 2026-10-08T12:00:00.000Z Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA) https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-japanese-patent-allowance BiopharmaWatch en 2026-10-08T12:00:00.000Z bioAffinity Technologies Announces Notification of Japanese Patent Allowance Covering Noninvasive CyPath® Lung and AI-Built Algorithm https://www.biopharmawatch.com/news/INCY/incyte-third-quarter-financial-results BiopharmaWatch en 2026-10-08T12:00:00.000Z Incyte to Report Third Quarter Financial Results https://www.biopharmawatch.com/news/LTRN/lantern-pharma-thinkequity-conference-2026 BiopharmaWatch en 2026-10-08T12:00:00.000Z Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 15th, 2026 https://www.biopharmawatch.com/news/LUCY/innovative-eyewear-launches-lucyd-aero-smart-glasses BiopharmaWatch en 2026-10-08T12:00:00.000Z Innovative Eyewear, Inc. Launches Lucyd Aero https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-equinox-hfpef-trial-edg-15400 BiopharmaWatch en 2026-10-08T12:00:00.000Z Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400 https://www.biopharmawatch.com/news/TECH/bio-techne-expands-gmp-manufacturing-bristol-facility BiopharmaWatch en 2026-10-08T12:00:00.000Z Bio-Techne Expands Global GMP Manufacturing Network with New Bristol Facility to Advance Scalable Cell Therapy Development https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-certespetide-pancreatic-cancer-patent BiopharmaWatch en 2026-10-08T12:00:00.000Z Lisata Therapeutics Announces New Method of Use Patent Granted for Certepetide in the Treatment of Pancreatic Cancer and Other Solid Tumors https://www.biopharmawatch.com/news/XAIR/beyond-air-preannounces-revenue-q3-2026 BiopharmaWatch en 2026-10-08T12:00:00.000Z Beyond Air® Preannounces Preliminary Revenue for the Quarter Ended September 30, 2026 https://www.biopharmawatch.com/news/ENOV/enovis-third-quarter-2026-results-conference-call BiopharmaWatch en 2026-10-08T12:00:00.000Z Enovis to Host Third Quarter 2026 Results Conference Call on November 5th https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-acg-2026-voquezna-data BiopharmaWatch en 2026-10-08T12:00:00.000Z Phathom Pharmaceuticals to Present New Data and Analyses for VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting https://www.biopharmawatch.com/news/ENTX/entera-bio-eb613-phase-3-study-asbmr-2026 BiopharmaWatch en 2026-10-08T12:00:00.000Z Entera Bio Announces Additional Presentation of EB613 Phase 3 Study Design at the ASBMR 2026 Annual Meeting https://www.biopharmawatch.com/news/AMRX/amneal-third-quarter-2026-results BiopharmaWatch en 2026-10-08T12:00:00.000Z Amneal to Report Third Quarter 2026 Results on November 3, 2026 https://www.biopharmawatch.com/news/AARD/aardvark-therapeutics-appoints-david-zhang BiopharmaWatch en 2026-10-08T12:00:00.000Z Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its Board of Directors https://www.biopharmawatch.com/news/VTRS/viatris-acquires-pacira-biosciences-non-opioid-pain-therapies BiopharmaWatch en 2026-10-08T11:45:00.000Z Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies https://www.biopharmawatch.com/news/CMND/clearmind-patent-publication-japan-dyskinesia-treatment BiopharmaWatch en 2026-10-08T11:32:00.000Z Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder https://www.biopharmawatch.com/news/HYPR/hyperfine-reports-third-quarter-revenue-outlook-2026 BiopharmaWatch en 2026-10-08T11:30:00.000Z Hyperfine Reports Record Preliminary Third Quarter Revenue of Approximately $6.0 Million & Reaffirms Full Year 2026 Revenue Outlook of Approximately $20 to $22 Million https://www.biopharmawatch.com/news/HYPR/hyperfine-announces-q3-2026-results-date BiopharmaWatch en 2026-10-08T11:30:00.000Z Hyperfine, Inc. to Announce Third Quarter 2026 Financial Results on November 9, 2026 https://www.biopharmawatch.com/news/AGEN/armenian-marketing-authorization-agenus-bot-bal BiopharmaWatch en 2026-10-08T11:30:00.000Z Armenia Grants First Marketing Authorizations for Agenus’ BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-mstoronto2026-data-presentations BiopharmaWatch en 2026-10-08T11:30:00.000Z TG Therapeutics Announces Schedule of Data Presentations at MSToronto2026 https://www.biopharmawatch.com/news/CRON/cronos-group-2026-q3-earnings-call BiopharmaWatch en 2026-10-08T11:30:00.000Z Cronos Group Inc. to Hold 2026 Third Quarter Earnings Conference Call on November 5, 2026 https://www.biopharmawatch.com/news/CNSY/cerenome-florida-blue-cnside-agreement BiopharmaWatch en 2026-10-08T11:30:00.000Z Cerenome Secures In-Network Agreement with Florida Blue for CNSide® CSF Tumor Cell Enumeration and Molecular Profile Tests https://www.biopharmawatch.com/news/HELP/helus-pharma-investor-presentation-october-2026 BiopharmaWatch en 2026-10-08T11:30:00.000Z Helus Pharma to Host Investor Presentation on October 21, 2026 https://www.biopharmawatch.com/news/DTIL/precision-biosciences-late-breaking-presentation-aasld-2026 BiopharmaWatch en 2026-10-08T11:01:00.000Z Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting 2026 https://www.biopharmawatch.com/news/XFOR/x4-pharmaceuticals-secures-debt-facility-k2-healthventures BiopharmaWatch en 2026-10-08T11:00:38.000Z X4 Pharmaceuticals Secures Up to $150 Million Senior Debt Facility with K2 HealthVentures https://www.biopharmawatch.com/news/AGIO/agios-third-quarter-2026-financial-results-call BiopharmaWatch en 2026-10-08T11:00:00.000Z Agios to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5 at 8:00 a.m. ET https://www.biopharmawatch.com/news/GKOS/glaukos-exclusive-license-agreement-revopsis-therapeutics BiopharmaWatch en 2026-10-08T11:00:00.000Z Glaukos Announces Exclusive License Agreement with RevOpsis Therapeutics to Develop and Commercialize RO-104, a First-in-Class Tri-Specific Biologic for Retinal Diseases https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-npulse-technology-vt-symposium-2026 BiopharmaWatch en 2026-10-08T11:00:00.000Z Pulse Biosciences’ nPulse™ Technology to be Featured at the 21st Annual International VT Symposium 2026 https://www.biopharmawatch.com/news/HSIC/henry-schein-cfo-leadership-transition BiopharmaWatch en 2026-10-08T11:00:00.000Z Henry Schein Announces Chief Financial Officer Leadership Transition https://www.biopharmawatch.com/news/BLRX/biolinerx-hemispherian-glix1-sno-meeting-2026 BiopharmaWatch en 2026-10-08T11:00:00.000Z BioLineRx and Hemispherian Announce Two GLIX1 Presentations at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education Day https://www.biopharmawatch.com/news/SI/shoulder-innovations-launch-inset-go BiopharmaWatch en 2026-10-08T11:00:00.000Z Shoulder Innovations Initiates Commercial Launch of the InSet® Go https://www.biopharmawatch.com/news/TLRY/tilray-brands-record-q1-fiscal-2027-revenue BiopharmaWatch en 2026-10-08T11:00:00.000Z Tilray Brands Delivers Record Q1 Fiscal 2027 Revenue and Record Q1 Gross Profit, Demonstrating the Power of Its Global Platform, Driven by Double-Digit Year-Over-Year Growth Across International Cannabis, Beverage and Pharmaceutical Distribution https://www.biopharmawatch.com/news/GANX/gain-therapeutics-maxim-growth-summit-2026 BiopharmaWatch en 2026-10-08T11:00:00.000Z Gain Therapeutics to Attend the 2026 Maxim Growth Summit https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-phase-2-study-cln-049-aml BiopharmaWatch en 2026-10-08T11:00:00.000Z Cullinan Therapeutics Announces First Patient Dosed in Planned Registrational Phase 2 Study of CLN-049 in Relapsed/Refractory Acute Myeloid Leukemia https://www.biopharmawatch.com/news/BSEM/biostem-ceo-coo-invest-one-million-stock-options BiopharmaWatch en 2026-10-08T11:00:00.000Z BioStem Technologies’ CEO and COO Invest $1 Million in Cash Through Exercise of Stock Options https://www.biopharmawatch.com/news/EDIT/editas-medicine-phase-1-2-trial-approval BiopharmaWatch en 2026-10-08T11:00:00.000Z Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia https://www.biopharmawatch.com/news/ACON/aclarion-clarity-trial-enrollment-criteria-update BiopharmaWatch en 2026-10-08T11:00:00.000Z Aclarion Broadens CLARITY Trial Enrollment Criteria to Accelerate Enrollment https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-chardan-healthcare-conference-2026 BiopharmaWatch en 2026-10-08T11:00:00.000Z Lexeo Therapeutics to Participate in the Chardan Healthcare Conference https://www.biopharmawatch.com/news/BMY/zenbexustm-iberdomide-phase-3-results-multiple-myeloma BiopharmaWatch en 2026-10-08T10:59:00.000Z Bristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior Progression-Free Survival vs. Standard of Care in Relapsed and Refractory Multiple Myeloma in Phase 3... https://www.biopharmawatch.com/news/DNA/araceli-ginkgo-imagenes-celulares-nebula BiopharmaWatch en 2026-10-08T10:39:00.000Z Araceli Biosciences y Ginkgo Bioworks incorporan la obtención de imágenes celulares al laboratorio de Nebula https://www.biopharmawatch.com/news/RNA/atrium-therapeutics-announces-50-million-private-placement BiopharmaWatch en 2026-10-08T10:30:00.000Z Atrium Therapeutics Announces $50 Million Private Placement https://www.biopharmawatch.com/news/CATX/perspective-therapeutics-fast-track-psv359 BiopharmaWatch en 2026-10-08T10:16:00.000Z Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous Tumors https://www.biopharmawatch.com/news/ANGO/angiodynamics-fiscal-year-2027-q1-results BiopharmaWatch en 2026-10-08T10:02:00.000Z AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability https://www.biopharmawatch.com/news/ANGO/angiodynamics-appoints-eric-honroth-ceo BiopharmaWatch en 2026-10-08T10:00:00.000Z AngioDynamics Announces Appointment of Eric Honroth as President and Chief Executive Officer https://www.biopharmawatch.com/news/WST/west-third-quarter-2026-conference-call BiopharmaWatch en 2026-10-08T10:00:00.000Z West to Host Third-Quarter 2026 Conference Call https://www.biopharmawatch.com/news/DNA/araceli-ginkgo-cellular-imaging-integration BiopharmaWatch en 2026-10-08T10:00:00.000Z Araceli Biosciences and Ginkgo Bioworks Bring Cellular Imaging at Scale to Nebula's Lab-in-the-Loop https://www.biopharmawatch.com/news/CVS/aetna-2027-medicare-plans-access-care-support BiopharmaWatch en 2026-10-08T08:45:00.000Z Aetna 2027 Medicare Plans Offer Reliable, Affordable Access to Care & Member Support https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-public-offering-pricing BiopharmaWatch en 2026-10-08T08:00:00.000Z Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public Offering https://www.biopharmawatch.com/news/BHVN/biohaven-licensing-agreement-ono-pharma-bhv-1300 BiopharmaWatch en 2026-10-08T08:00:00.000Z Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease https://www.biopharmawatch.com/news/MBX/microbix-keynote-masters-summit-2026 BiopharmaWatch en 2026-10-08T07:00:00.000Z Microbix Making Keynote Presentation at Masters Summit 2026 https://www.biopharmawatch.com/news/ADXN/addex-spin-neurosterix-completes-phase-1-clinical-studies-ntx-253 BiopharmaWatch en 2026-10-08T05:00:00.000Z Addex Spin-Out Neurosterix Completes Phase 1 Clinical Studies of NTX-253 for Schizophrenia https://www.biopharmawatch.com/news/ARGX/argenx-phase-2-results-fb102-celiac-disease BiopharmaWatch en 2026-10-08T05:00:00.000Z argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease https://www.biopharmawatch.com/news/ARGX/argenx-phase-3-unity-study-update-sjogrens-disease BiopharmaWatch en 2026-10-08T05:00:00.000Z argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's Disease https://www.biopharmawatch.com/news/MDT/medtronic-final-exchange-ratio-minimed-separation BiopharmaWatch en 2026-10-07T21:31:00.000Z Medtronic Announces Final Exchange Ratio of 4.5939 in Split-Off of MiniMed Group, Inc. https://www.biopharmawatch.com/news/HIMS/hims-hers-names-jon-franklin-chief-accounting-officer BiopharmaWatch en 2026-10-07T20:17:00.000Z Hims & Hers Names Jon Franklin as Chief Accounting Officer https://www.biopharmawatch.com/news/IQV/iqvia-launches-explorer-commercial-decisions BiopharmaWatch en 2026-10-07T20:15:00.000Z IQVIA Launches IQVIA Explorer to Help Life Sciences Companies Make Better Commercial Decisions https://www.biopharmawatch.com/news/BAX/baxter-third-quarter-2026-financial-results-call BiopharmaWatch en 2026-10-07T20:15:00.000Z Baxter to Host Third-Quarter 2026 Financial Results Conference Call for Investors https://www.biopharmawatch.com/news/IQV/iqvia-launches-life-science-models-predict-clinical-trial-outcomes BiopharmaWatch en 2026-10-07T20:15:00.000Z IQVIA Launches IQVIA Life Science Models to Help Life Sciences Companies Predict Clinical Trial Outcomes https://www.biopharmawatch.com/news/PROF/profound-medical-q3-2026-revenue-report BiopharmaWatch en 2026-10-07T20:15:00.000Z Profound Medical Reports Strong Preliminary Third Quarter 2026 Revenue https://www.biopharmawatch.com/news/HCSG/prime-healthcare-services-2026-earnings-call BiopharmaWatch en 2026-10-07T20:09:00.000Z Prime Healthcare Services, Inc. Schedules 2026 3rd Quarter Earnings Conference Call https://www.biopharmawatch.com/news/ALEC/alector-virtual-event-abc-enabled-pipeline BiopharmaWatch en 2026-10-07T20:05:00.000Z Alector to Host Virtual Research and Development Event Highlighting Wholly Owned Alector Brain Carrier (ABC)- Enabled Pipeline https://www.biopharmawatch.com/news/GKOS/glaukos-positive-epioxa-results-keratoconus BiopharmaWatch en 2026-10-07T20:05:00.000Z Glaukos Announces Positive Three-Year Epioxa® Results Demonstrating Durable Clinical Outcomes in Keratoconus https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-participate-industry-conferences BiopharmaWatch en 2026-10-07T20:05:00.000Z Lifecore Biomedical to Participate at Upcoming Industry Conferences https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-fda-orphan-drug-designation-hppd-sickle-cell BiopharmaWatch en 2026-10-07T20:01:00.000Z vTv Therapeutics Announces FDA Orphan Drug Designation for HPPD in Sickle Cell Disease https://www.biopharmawatch.com/news/VRTX/vertex-announces-q3-2026-financial-results BiopharmaWatch en 2026-10-07T20:00:00.000Z Vertex to Announce Third Quarter 2026 Financial Results November 2nd https://www.biopharmawatch.com/news/VALN/valneva-ixchiq-uk-market-authorization-update BiopharmaWatch en 2026-10-07T20:00:00.000Z Valneva fait un point sur l’utilisation d’IXCHIQ® au Royaume-Uni https://www.biopharmawatch.com/news/VALN/valneva-update-ixchiq-uk BiopharmaWatch en 2026-10-07T20:00:00.000Z Valneva Provides Update on IXCHIQ® in the United Kingdom https://www.biopharmawatch.com/news/ZEAL/zealand-pharma-positive-phase-2-results-petrelintide BiopharmaWatch en 2026-10-07T17:14:00.000Z Zealand Pharma announces positive Phase 2 ZUPREME-2 topline results for amylin analog petrelintide in people with overweight or obesity and type 2 diabetes https://www.biopharmawatch.com/news/SPTX/seaport-therapeutics-first-patient-dosed-phase-2a-trial BiopharmaWatch en 2026-10-07T17:00:00.000Z PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo™ in Patients with Generalized Anxiety Disorder and Sleep Disturbance https://www.biopharmawatch.com/news/PFE/pfizer-tukysa-fda-approval-her2-breast-cancer BiopharmaWatch en 2026-10-07T16:57:00.000Z Pfizer’s TUKYSA Regimen Receives FDA Approval as Front-Line Maintenance Treatment for HER2+ Metastatic Breast Cancer https://www.biopharmawatch.com/news/GMAB/genmab-extraordinary-general-meeting-2026-remuneration BiopharmaWatch en 2026-10-07T16:17:00.000Z Resolution Adopted at the Extraordinary General Meeting of Genmab A/S Including Grant of Restricted Stock Units to Board Members https://www.biopharmawatch.com/news/NVS/novartis-rhapsido-fda-approval-symptomatic-dermographism BiopharmaWatch en 2026-10-07T15:45:00.000Z Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU) https://www.biopharmawatch.com/news/FMS/shervin-korangy-ceo-fresenius-medical-care BiopharmaWatch en 2026-10-07T15:28:00.000Z Shervin J. Korangy appointed CEO of Fresenius Medical Care to lead the next phase of strategic development and long-term profitable growth https://www.biopharmawatch.com/news/CVS/cvs-pharmacy-first-location-boston BiopharmaWatch en 2026-10-07T15:00:00.000Z CVS Pharmacy® celebrates opening of first pharmacy-focused location in Boston area https://www.biopharmawatch.com/news/ASTH/alignment-health-expands-california-2027 BiopharmaWatch en 2026-10-07T15:00:00.000Z Alignment Health Expands to Three New California Counties and Adds Hoag and Astrana Health for 2027